Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Shirley R. Kuhlmann Sells 27,500 Shares

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Shirley R. Kuhlmann sold 27,500 shares of the firm’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the sale, the executive vice president now owns 119,184 shares in the company, valued at $3,937,839.36. This trade represents a 18.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Collegium Pharmaceutical Price Performance

Shares of COLL stock traded down $0.61 during trading hours on Tuesday, reaching $33.18. The company had a trading volume of 283,240 shares, compared to its average volume of 545,422. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The stock has a fifty day moving average of $30.58 and a 200-day moving average of $34.09. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of 14.30 and a beta of 0.82. Collegium Pharmaceutical, Inc. has a 12-month low of $28.39 and a 12-month high of $42.29.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Pacer Advisors Inc. grew its holdings in shares of Collegium Pharmaceutical by 31.8% during the 2nd quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock worth $109,749,000 after purchasing an additional 821,541 shares during the period. Rubric Capital Management LP lifted its position in Collegium Pharmaceutical by 27.2% in the second quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock valued at $75,139,000 after buying an additional 499,473 shares during the last quarter. Victory Capital Management Inc. boosted its stake in Collegium Pharmaceutical by 43.6% during the third quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock worth $27,461,000 after buying an additional 215,874 shares during the period. Emerald Advisers LLC increased its position in shares of Collegium Pharmaceutical by 27.2% during the third quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock valued at $31,967,000 after acquiring an additional 177,129 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Collegium Pharmaceutical by 173.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after acquiring an additional 175,892 shares during the period.

Wall Street Analyst Weigh In

COLL has been the topic of several research analyst reports. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research report on Friday. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Friday. Finally, Piper Sandler reiterated a “neutral” rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $43.80.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.